Works matching IS 15391604 AND DT 2019 AND VI 18 AND IP 3

Results: 12

Hazard ratio inference in stratified clinical trials with time‐to‐event endpoints and limited sample size.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 366, doi. 10.1002/pst.1928

By:

Xu, Rengyi;
Mehrotra, Devan V.;
Shaw, Pamela A.

Publication type:

Article

Nested combination tests with a time‐to‐event endpoint using a short‐term endpoint for design adaptations.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 329, doi. 10.1002/pst.1926

By:

Jörgens, Silke;
Wassmer, Gernot;
König, Franz;
Posch, Martin

Publication type:

Article

A comparative study of confidence intervals to assess biosimilarity from analytical data.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 316, doi. 10.1002/pst.1925

By:

Quiroz, Jorge;
Montes, Richard;
Shi, Heliang;
Roychoudhury, Satrajit

Publication type:

Article

Assessing the predictive value of a binary surrogate for a binary true endpoint based on the minimum probability of a prediction error.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 304, doi. 10.1002/pst.1924

By:

Meyvisch, Paul;
Alonso, Ariel;
Van der Elst, Wim;
Molenberghs, Geert

Publication type:

Article

Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 287, doi. 10.1002/pst.1923

By:

Jiménez, José L.;
Stalbovskaya, Viktoriya;
Jones, Byron

Publication type:

Article

Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593‐606, Sep/Oct 2018., DOI:https://doi.org/10.1002/pst.1873

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 284, doi. 10.1002/pst.1942

By:

Jaki, Thomas;
Gordon, Allan;
Forster, Pamela;
Bijnens, Luc;
Bornkamp, Bjoern;
Brannath, Werner;
Fontana, Roberto;
Gasparini, Mauro;
Hampson, Lisa V.;
Jacobs, Tom;
Jones, Byron;
Paoletti, Xavier;
Posch, Martin;
Titman, Andrew;
Vonk, Richardus;
Koenig, Franz

Publication type:

Article

Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593–606, Sep/Oct 2018, DOI: 10.1002/pst.1873.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 278, doi. 10.1002/pst.1940

By:

Krause, Andreas;
Kloft, Charlotte;
Huisinga, Wilhelm;
Karlsson, Mats;
Pinheiro, José;
Bies, Robert;
Rogers, James;
Mentré, France;
Musser, Bret J

Publication type:

Article

Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17(5):593–606, Sep/Oct 2018. DOI: 10.1002/pst.1873.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 282, doi. 10.1002/pst.1939

By:

Burger, Hans Ulrich

Publication type:

Article

Assessment of individual bioequivalence using sufficient bootstrap procedure.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 388, doi. 10.1002/pst.1930

By:

Beyaztas, Ufuk

Publication type:

Article

Tests for noninferiority trials with binomial endpoints: A guide to modern and quasi‐exact methods for biomedical researchers.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 377, doi. 10.1002/pst.1929

By:

Ripamonti, Enrico;
Lloyd, Chris J.

Publication type:

Article

Blinded sample size reestimation in event‐driven clinical trials: Methods and an application in multiple sclerosis.

Published in:

Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 351, doi. 10.1002/pst.1927

By:

Friede, Tim;
Pohlmann, Harald;
Schmidli, Heinz

Publication type:

Article

Issue Information.

Published in:: Pharmaceutical Statistics, 2019, v. 18, n. 3, p. 275, doi. 10.1002/pst.1883
Publication type:: Article